Where does Xvivo Perfusion AB rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Xvivo Perfusion AB ranks #44,174 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Xvivo Perfusion AB hold?

Xvivo Perfusion AB holds 6 US utility patents granted between 2015 and 2025, spanning 7 technology areas.

What is Xvivo Perfusion AB's Innovation Score?

Xvivo Perfusion AB has an Innovation Score of 29.7 out of 100 (32nd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Xvivo Perfusion AB's patent grant rate increasing or decreasing?

Xvivo Perfusion AB's recent grant velocity is -75% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Xvivo Perfusion AB's patents?

Xvivo Perfusion AB's patents average 17.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Xvivo Perfusion AB patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Xvivo Perfusion AB

Q: What technology areas does Xvivo Perfusion AB focus on?

Xvivo Perfusion AB's top technology area is A01N (Preservation OF Bodies OF Humans OR Animals OR Plants OR Parts Thereof ; Biocides, e.g. AS Disinfectants, AS Pesticides OR AS Herbicides ; Pest Repellants OR ATTRACTANTS; Plant Growth Regulators) with 5 patents, ranking #283 of 1,216 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

USPTO PatentsView assignee record - 6 granted patents across 7 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A01N (Preservation OF Bodies OF Humans OR Animals OR Plants OR Parts Thereof ; Biocides, e.g. AS Disinfectants, AS Pesticides OR AS Herbicides ; Pest Repellants OR ATTRACTANTS; Plant Growth Regulators).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Xvivo ranks #44,174 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 7 technology areas.

#44,174
of 49,997 US assignees by volume: 32nd percentile
by Innovation Score (29.7/100): 17.2
avg claims per patent: -75%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R44174 · Foreign Corporation #44,174 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 6 grants
LOWER-Q #44,174/49,997
PHOTO-FINISH Xact Laboratories
CPC-NARROW A01N · 7 areas
INNOV-THIN 29.7/100
CLAIMS-RICH 17.2 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -75% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Xact Laboratories, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Xvivo’s 29.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.7 pts (23%) Velocity 3.3 pts (11%) Breadth 9.4 pts (32%) Claim depth 10.3 pts (35%)

Qualcomm Incorporated · highest

85
Xvivo Perfusion AB · this assignee

30
3D Lighting… · lowest

7

What this shows Xvivo's Innovation Score is 29.7/100 (32nd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Xvivo?

Each dot is one of Xvivo’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Xvivo’s own 17.2 claims/patent is ABOVE the 12.2 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Xvivo vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Xvivo's grants concentrate

Xvivo Perfusion AB is a focused PatentsView assignee: 7 CPC subclasses with 83.3% of grants classified under A01N (Preservation OF Bodies OF Humans OR Animals OR Plants OR Parts Thereof ; Biocides, e.g. AS Disinfectants, AS Pesticides OR AS Herbicides ; Pest Repellants OR ATTRACTANTS; Plant Growth Regulators). Peak complete grant year is 2015 (2 grants) versus a trough of 1 in 2023. By volume, Xvivo sits between Xraydepot LLC and Xact Laboratories, LLC.

Xvivo's three-year grant acceleration

Xvivo Perfusion AB shows 1 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Xraydepot

6
Xtralis Global

6
Xuanzhu Biopharma…

6
Xuzhou Zhirun Min…

6
Xyphos Biosciences

6
XYZ Energy Group

6
XYZ Interactive

6
Xact Laboratories

6
Xvivo Perfusion AB ◀

6

What this shows Xvivo holds 6 patents at rank #44,126, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Xvivo

By rank, the assignees closest to #44,126 in granted patent volume.

Leaders in A01N (Preservation OF Bodies OF Humans OR Animals OR Plants OR…)

Other assignees with the most granted patents in Xvivo's primary technology class.

Xvivo's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

30 32nd percentile higher than 32% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Xvivo Perfusion AB patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	33.3%
2019	2	33.3%
2023	1	16.7%
2025partial year	1	16.7%

Which technologies does Xvivo Perfusion AB patent most?

A01N - Preservation OF Bodies OF Humans OR Animals OR Plants OR Parts Thereof ; Biocides, e.g. AS Disinfectants, AS Pesticides OR AS Herbicides ; Pest Repellants OR ATTRACTANTS; Plant Growth Regulators 5

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 2

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 1

A61B - DIAGNOSIS; SURGERY; Identification 1

G09B - Educational OR Demonstration APPLIANCES; Appliances FOR Teaching, OR Communicating With, THE Blind, Deaf OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; Diagrams 1

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Xvivo Perfusion AB's patent record in context - here's where to go next.

Xvivo Perfusion AB's lead technology class is A01N (Preservation OF Bodies OF Humans OR Animals OR Plants OR Parts Thereof ; Biocides, e.g. AS Disinfectants, AS Pesticides OR AS Herbicides ; Pest Repellants OR ATTRACTANTS; Plant Growth Regulators), 83.3% of its portfolio - see every assignee active in that class. Explore A01N
Ranked #44,174 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Xvivo Perfusion AB against Xraydepot LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 29.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.